2. Academic Validation
  3. Antibody-drug conjugates for targeted cancer therapy: Recent advances in potential payloads

Antibody-drug conjugates for targeted cancer therapy: Recent advances in potential payloads

  • Eur J Med Chem. 2024 Oct 5:276:116709. doi: 10.1016/j.ejmech.2024.116709.
Meiyang Xi 1,  Jingjing Zhu 2,  Fengxia Zhang 2,  Hualiang Shen 1,  Jianhui Chen 3,  Ziyan Xiao 3,  Yanping Huangfu 3,  Chunlei Wu 1,  Haopeng Sun 4,  Gang Xia 2
Affiliations

Affiliations

  • 1 Zhejiang Engineering Research Center of Fat-soluble Vitamin, Shaoxing University, Shaoxing, 312000, China; College of Chemistry and Chemical Engineering, Shaoxing University, Shaoxing, 312000, China.
  • 2 NovoCodex Biopharmaceuticals Co. Ltd., Shaoxing, 312090, China.
  • 3 College of Chemistry and Chemical Engineering, Shaoxing University, Shaoxing, 312000, China.
  • 4 Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing, 210009, China. Electronic address: [email protected].
PMID: 39068862 DOI: 10.1016/j.ejmech.2024.116709
Abstract

Antibody-drug conjugates (ADCs) represent a promising Cancer therapy modality which specifically delivers highly toxic payloads to Cancer cells through antigen-specific monoclonal antibodies (mAbs). To date, 15 ADCs have been approved and more than 100 ADC candidates have advanced to clinical trials for the treatment of various cancers. Among these ADCs, microtubule-targeting and DNA-damaging agents are at the forefront of payload development. However, several challenges including toxicity and drug resistance limit the potential of this modality. To tackle these issues, multiple innovative payloads such as immunomodulators and proteolysis targeting chimeras (PROTACs) are incorporated into ADCs to enable multimodal Cancer therapy. In this review, we describe the mechanism of ADCs, highlight the importance of ADC payloads and summarize recent progresses of conventional and unconventional ADC payloads, trying to provide an insight into payload diversification as a key step in future ADC development.

Keywords

Antibody-drug conjugate (ADC); Cancer therapy; Payload.

Figures